Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Rusfertide [usan]
2. Xm71myx0iq
3. Ptg-300fb
4. Ptg-300
5. 1628323-80-7
6. Isovaleryl-asp-thr-his-phe-pro-cyclo(cys-ile-lys(palm-gamma-glu)- Phe-glu-pro-arg-ser-lys-gly-cys)-lys-nh2
7. Rusfertide [inn]
8. Unii-xm71myx0iq
9. Who 11456
10. L-lysinamide, N-(3-methyl-1-oxobutyl)-l-.alpha.-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-l-cysteinyl-l-isoleucyl-n6-(n-(1-oxohexadecyl)-l-.gamma.-glutamyl)-l-lysyl-l-phenylalanyl-l-.alpha.-glutamyl-l-prolyl-l-arginyl-l-seryl-l-lysylglycyl-l-cysteinyl-
11. N-(3-methyl-1-oxobutyl)-l-.alpha.-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-l-cysteinyl-l-isoleucyl-n6-(n-(1-oxohexadecyl)-l-.gamma.-glutamyl)-l-lysyl-l-phenylalanyl-l-.alpha.-glutamyl-l-prolyl-l-arginyl-l-seryl-l-lysylglycyl-l-cysteinyl-l-lysinamide
| Molecular Weight | 2442.0 g/mol |
|---|---|
| Molecular Formula | C114H181N27O28S2 |
| XLogP3 | -1.5 |
| Hydrogen Bond Donor Count | 29 |
| Hydrogen Bond Acceptor Count | 34 |
| Rotatable Bond Count | 67 |
| Exact Mass | 2441.3044354 g/mol |
| Monoisotopic Mass | 2440.3010806 g/mol |
| Topological Polar Surface Area | 924 Ų |
| Heavy Atom Count | 171 |
| Formal Charge | 0 |
| Complexity | 5090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 19 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
In a divestment deal, Rusfertide, an unconjugated peptide targeting hepcidin, is being sold to focus on polycythemia vera treatment.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: $1,750.0 million Upfront Cash: $300.0 million
Deal Type: Divestment April 28, 2026
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : $1,750.0 million
Deal Type : Divestment
Protagonist Exercises Rusfertide U.S. Opt-Out Right with Takeda Collaboration
Details : In a divestment deal, Rusfertide, an unconjugated peptide targeting hepcidin, is being sold to focus on polycythemia vera treatment.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $300.0 million
April 28, 2026
Details:
PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2025
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist, Takeda Announce Positive Phase 3 VERIFY Study Results
Details : PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 03, 2025
Details:
PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2024
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist Therapeutics Updates on VERIFY Patient Enrollment and Timing of Top-line Data
Details : PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 26, 2024
Details:
The collaboration supports PTG-300 (rusfertide) development for Polycythemia Vera, with the protagonist responsible for research and completing the Phase 3 trial and U.S. regulatory approval.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration March 18, 2024
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Protagonist Announces License and Collaboration Agreement with Takeda
Details : The collaboration supports PTG-300 (rusfertide) development for Polycythemia Vera, with the protagonist responsible for research and completing the Phase 3 trial and U.S. regulatory approval.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $300.0 million
March 18, 2024
Details:
The collaboration supports the development of PTG-300 (rusfertide) for Polycythemia Vera. The protagonist is responsible for completing the Phase 3 trial and U.S. regulatory approval.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration January 31, 2024
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Takeda and Protagonist Enter Worldwide License for Rusfertide
Details : The collaboration supports the development of PTG-300 (rusfertide) for Polycythemia Vera. The protagonist is responsible for completing the Phase 3 trial and U.S. regulatory approval.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $300.0 million
January 31, 2024
Details:
Rusfertide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2023
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Details : Rusfertide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 13, 2023
Details:
The net proceeds intends to fund the continued clinical development and pre-commercialization activities associated with PTG-300 (rusfertide), an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 04, 2023
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
Details : The net proceeds intends to fund the continued clinical development and pre-commercialization activities associated with PTG-300 (rusfertide), an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
April 04, 2023
Details:
PTG-300 (rusfertide) is a hepcidin-mimetic that helps reduce iron availability to help achieve hematocrit control and decrease erythropoiesis in patients with polycythemia vera (PV) without the need for periodic therapeutic phlebotomy.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 15, 2023
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PTG-300 (rusfertide) is a hepcidin-mimetic that helps reduce iron availability to help achieve hematocrit control and decrease erythropoiesis in patients with polycythemia vera (PV) without the need for periodic therapeutic phlebotomy.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 15, 2023
Details:
Rusfertide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2022
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Details : Rusfertide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 27, 2022
Details:
The rasH2 signal also prompted a re-examination of the four cases of cancer observed across all rusfertide clinical trials involving over 160 patients, and a comprehensive review of the safety database, including cases of suspected unexpected serious adverse reactions (SUSAR).
Lead Product(s): Rusfertide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2021
Lead Product(s) : Rusfertide,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The rasH2 signal also prompted a re-examination of the four cases of cancer observed across all rusfertide clinical trials involving over 160 patients, and a comprehensive review of the safety database, including cases of suspected unexpected serious adv...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
61
PharmaCompass offers a list of Rusfertide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rusfertide manufacturer or Rusfertide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rusfertide manufacturer or Rusfertide supplier.
A Rusfertide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rusfertide, including repackagers and relabelers. The FDA regulates Rusfertide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rusfertide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rusfertide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Rusfertide supplier is an individual or a company that provides Rusfertide active pharmaceutical ingredient (API) or Rusfertide finished formulations upon request. The Rusfertide suppliers may include Rusfertide API manufacturers, exporters, distributors and traders.
click here to find a list of Rusfertide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
Rusfertide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rusfertide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rusfertide GMP manufacturer or Rusfertide GMP API supplier for your needs.
A Rusfertide CoA (Certificate of Analysis) is a formal document that attests to Rusfertide's compliance with Rusfertide specifications and serves as a tool for batch-level quality control.
Rusfertide CoA mostly includes findings from lab analyses of a specific batch. For each Rusfertide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rusfertide may be tested according to a variety of international standards, such as European Pharmacopoeia (Rusfertide EP), Rusfertide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rusfertide USP).
